Biocair has announced it is creating a specialist logistics team to cope with the rapidly expanding cell and gene therapy sector.
The team will comprise over 30 specialists to deliver 24 hour support for cell and gene therapy service users.
Biocair UK Cell and Gene Therapy Lead, Kinga Lovasz said: "With the creation of a dedicated cell and gene therapy team, Biocair is leading the future of life science logistics towards greater personalisation and helping the industry to build the infrastructure required to support this new era of treatment.
Patient centricity and sample integrity are paramount, requiring unique responses to specific needs.
The cell and gene therapy market was valued at USD 4.99 billion in 2021 and is forecast to reach USD 36.92 billion by 2027, according to the Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027.
She added: "This new team of experts will enhance Biocair's agility in the field and enable us to develop new logistics solutions, such as advanced packaging and tracking technologies, to ensure materials arrive on-time and in-full anywhere across the globe.
Additional investments are also being made in other areas of the business, including packaging, IT and other support services, to aid the growth of the cell and gene therapy division.
As a sector, cell and gene therapy increasingly requires personalised solutions, including temperature-controlled packaging and logistics, to successfully navigate unique supply chains to deliver on-time, in-full.
“Patient centricity and sample integrity are paramount, requiring unique responses to specific needs. This focus on curing rather than treating symptoms requires complex products, which in turn increases the need for more complex logistical solutions," said Lovasz.
